Radical prostatectomy for prostate cancer patients with prostate-specific antigen >20 ng/ml

Japanese Journal of Clinical Oncology

Volumn 33, Issue 11, 2003, Pages 574-579

  Ou, Yen Chuan ^a,b   Chen, Jung Ta ^a,b   Cheng, Chen Li ^a   Ho, Hao Chung ^a   Yang, Chi Rei ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adenocarcinoma; Prostate; Prostate specific antigen; Prostatectomy; PSA

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER METASTASIS; CANCER CLASSIFICATION; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SEMINAL VESICLE DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME; BLOOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; SURVIVAL RATE;

AGED; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 1342268244     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg104     Document Type: Article

References (24)

1. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997;277:1445-51.
2. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. Urology 1993; 150:110-4.
3. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843-8.
4. Reckwitz T, Potter SR, Partin AW. Prediction of locoregional extension and metastatic disease in prostate cancer: A review. World J Urol 2000;18: 165-72.
5. Feneley MR, Partin AW. Indicators of pathological stage of prostate cancer and their use in clinical practice. Urol Clin North Am 2001;28:443-58.
6. Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT, et al. Validation of Partin Tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000;164:1591-5.
7. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer Statistics 2GO1. CA Cancer J Clin 2001;51:15-36.
8. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996; 155:816-20.
9. Ou YC, Chen JT, Yang CR, Cheng CL, Ho HC, Kao YL, et al. Preoperative prediction of extracapsular tumor extension at radical retropubic prostatectomy in Taiwanese patients with T1c prostate cancer. Jpn J Clin Oncol 2002;32:172-6.
10. Pound CR, Partin AW, Eisenberg MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
11. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989;141:1076-83.
12. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphological features of clinically recognized versus incidental tumors. Cancer 1992;70:2313-8.
13. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989;141:873-9.
14. Blackwell KL, Bostwick DG, Myers RP, Zincke H, Oesterling JE. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: The influence of prostate specific antigen cancer density. J Urol 1994;151:1565-70.
15. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, et al. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;143:747-52.
16. Greene DR, Wheeler TM, Egawa S, Dunn JK, Scardino PT. A comparison of the morphological features of cancer arising in the transition and in the peripheral zone of the prostate. J Urol 1991;146:1069-76.
17. Stamey TA, Dietrick DD, Issa MM. Large, organ confined, impalpable transition zone prostate cancer: Association with metastatic levels of prostate specific antigen. J Urol 1993;149:510-5.
18. Matsui Y, Egawa S, Tsukayama C, Terai A, Kuwao S, Baba S, et al. Artificial neural network analysis for predicting pathological stage of clinically localized prostate cancer in the Japanese population. Jpn J Clin Oncol 2002;32:530-5.
19. D'Amico AV, Whittington R, Schultz D, Malkowicz SB, Tomaszewski JE, Wei A. Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol 1997;158:1422-6.
20. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001;165:119-25.
21. Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M, Han M, et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001; 57:1033-7.
22. Epstein JI, Partin AW, Potter SR, Walsh PC. Adenocarcinoma of the prostate invading the seminal vesicle: Prognostic stratification based on pathological parameters. Urology 2000;56:283-8.
23. Dash A, Sanda WG, Yu M, Taylor JMG, Fecko A, Rubin MA. Prostate cancer involving the bladder neck recurrence-free survival and implications for AJCC staging modification. Urology 2002;60:276-80.
24. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: A matched comparison. J Urol 1999;161:1223-7.